Compare Vanguard Ultra Short Bond ETF (VUSB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Ultra Short Bond ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Ultra Short Bond ETF trades at $49.71, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). Which is the better fit depends on your goals.
| VUSB | WGS | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $50.03 | $167.51 |
52-Week Low | $49.60 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUSB trades at $49.70, showing minimal daily movement with a slight 0.02% gain. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Recent dividend payments of $0.17-$0.18 per share indicate ongoing shareholder returns. Financial media highlights potential benefits from Federal Reserve policy shifts favoring short-term bonds.
The outlook remains cautiously optimistic given the ETF's focus on short-term bonds amid potential rate hikes. Key risks include interest rate sensitivity and market volatility. Analyst sentiment appears balanced, with technical indicators suggesting near-term consolidation around current price levels.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
